SAN MATEO, CA -- (MARKET WIRE) -- 12/21/2005 -- SciClone Pharmaceuticals (NASDAQ: SCLN) today reported data from its small, phase 2 proof-of-concept hepatocellular carcinoma (liver cancer) trial indicating a trend toward positive survival benefit in patients treated with ZADAXIN® plus trans arterial chemo-embolization (TACE) compared with patients treated with TACE alone. Specifically, a median survival of 994 days was observed for the 12 patients who received ZADAXIN plus TACE, compared with a median survival of only 399 days for the 13 patients who received TACE alone, the control arm. No difference was observed in tumor response between the treatment groups.
